JP2025515116A5 - - Google Patents

Info

Publication number
JP2025515116A5
JP2025515116A5 JP2024564989A JP2024564989A JP2025515116A5 JP 2025515116 A5 JP2025515116 A5 JP 2025515116A5 JP 2024564989 A JP2024564989 A JP 2024564989A JP 2024564989 A JP2024564989 A JP 2024564989A JP 2025515116 A5 JP2025515116 A5 JP 2025515116A5
Authority
JP
Japan
Prior art keywords
treg
foxp3
disease
cells
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515116A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2023/051200 external-priority patent/WO2023214182A1/en
Publication of JP2025515116A publication Critical patent/JP2025515116A/ja
Publication of JP2025515116A5 publication Critical patent/JP2025515116A5/ja
Pending legal-status Critical Current

Links

JP2024564989A 2022-05-05 2023-05-05 制御性t細胞の抑制活性を維持するための方法 Pending JP2025515116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202206570 2022-05-05
GB2206570.0 2022-05-05
PCT/GB2023/051200 WO2023214182A1 (en) 2022-05-05 2023-05-05 Method for maintaining suppressive activity of regulatory t cells

Publications (2)

Publication Number Publication Date
JP2025515116A JP2025515116A (ja) 2025-05-13
JP2025515116A5 true JP2025515116A5 (cg-RX-API-DMAC7.html) 2026-04-16

Family

ID=86387161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564989A Pending JP2025515116A (ja) 2022-05-05 2023-05-05 制御性t細胞の抑制活性を維持するための方法

Country Status (5)

Country Link
US (1) US20250283039A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519417A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515116A (cg-RX-API-DMAC7.html)
CN (1) CN119325506A (cg-RX-API-DMAC7.html)
WO (1) WO2023214182A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US12227756B2 (en) * 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
WO2019241549A1 (en) * 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
EP3980035A4 (en) * 2019-06-07 2023-08-23 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
GB202013477D0 (en) * 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
IL302591A (en) * 2020-11-09 2023-07-01 Quell Therapeutics Ltd Method for cryopreservation of transgenic regulatory T cells

Similar Documents

Publication Publication Date Title
Zeng et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance
Ratajczak et al. Immunological memory cells
Reutner et al. CD27 expression discriminates porcine T helper cells with functionally distinct properties
GB2587988A (en) Method for enhancing the suppressive properties of Treg cells
JP6017620B2 (ja) 単一細胞の細胞傷害性を査定するための組成物および方法
Pedros et al. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases
EP2899269B1 (en) Method for cloning t cell receptor
Gerdemann et al. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host
KR20190037243A (ko) 면역치료를 위한 티 세포 조성물
AU2021286255B2 (en) Adoptive T Cell therapy 2
US7932045B2 (en) Method of isolating and proliferating autologous antigen-specific CD8+ T cell using anti-4-1BB antibodies
JP2025028931A (ja) Ebv特異的免疫細胞
JP2019520823A5 (cg-RX-API-DMAC7.html)
CN117777271B (zh) 一种t细胞受体(tcr)及其用途
JP2021519069A5 (cg-RX-API-DMAC7.html)
JP2021518130A5 (cg-RX-API-DMAC7.html)
Laird et al. γδ T cells acquire effector fates in the thymus and differentiate into cytokine-producing effectors in a Listeria model of infection independently of CD28 costimulation
JP2023533613A (ja) Il-10を発現する複数ドナーcd4+t細胞及びその使用
CN117106061B (zh) 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用
CN119978140A (zh) 一种融合蛋白、人工抗原递呈分子及其在扩增nkt中的应用
CN117777270B (zh) 一种t细胞受体(tcr)及其用途
CN117659164A (zh) 识别ebv抗原的t细胞受体及其应用
EP4538366A1 (en) Enhancing lineage stability of therapeutic regulatory t cell products
EP3564365B1 (en) Transdifferentation of b lymphoid cells into t cells
Saez-Cirion et al. Memory CD8⁺ T Cells Co-expressing TCF1 and ID2 Combine Effector and Stem-like Functions in Persistent Infections